Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer

Fig. 1

Binding of anti-PN peptide to PN. a Phage binding to rPN, compared with blank phage and BSA was used as the negative control, b Peptide binding to non-denaturing cell lysate from PN-transfected BCA cells compared with mock transfected BCA cells and BSA/ was used rPN as negative/positive control (M = mock transfected and PN = PN-transfected), c Peptide binding to permeabilized PN-transfected BCA cells compared with mock transfected BCA cells, visualized by confocal microscope with 640X original magnification, nucleus was adjusted to similar brightness, and (d) Isothermal titration calorimetry analysis diagram from binding between anti-PN peptide and BSA or rPN compared with commercial anti-PN antibody

Back to article page